Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/ijms24109101
Keywords
prostatic neoplasms; abiraterone acetate; enzalutamide; prognosis; biomarkers; liquid biopsy; hsa-miR-16-5p; hsa-miR-145-5p; hsa-miR-20a-5p
Ask authors/readers for more resources
Prostate cancer (PCa) is a common malignancy and advanced PCa leads to metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the prognostic potential of miRNAs in liquid biopsies of mCRPC patients treated with ARAT agents. Low expression levels of miR-16-5p and miR-145-5p were associated with lower PFS in patients treated with abiraterone acetate. Low miR-20a-5p levels were associated with worse OS in patients with Gleason scores of <8.
Prostate cancer (PCa) is one of the most common malignancies among men worldwide. Inevitably, all advanced PCa patients develop metastatic castration-resistant prostate cancer (mCRPC), an aggressive phase of the disease. Treating mCRPC is challenging, and prognostic tools are needed for disease management. MicroRNA (miRNA) deregulation has been reported in PCa, constituting potential non-invasive prognostic biomarkers. As such, this study aimed to evaluate the prognostic potential of nine miRNAs in the liquid biopsies (plasma) of mCRPC patients treated with second-generation androgen receptor axis-targeted (ARAT) agents, abiraterone acetate (AbA) and enzalutamide (ENZ). Low expression levels of miR-16-5p and miR-145-5p in mCRPC patients treated with AbA were significantly associated with lower progression-free survival (PFS). The two miRNAs were the only predictors of the risk of disease progression in AbA-stratified analyses. Low miR-20a-5p levels in mCRPC patients with Gleason scores of <8 were associated with worse overall survival (OS). The transcript seems to predict the risk of death regardless of the ARAT agent. According to the in silico analyses, miR-16-5p, miR-145-5p, and miR-20a-5p seem to be implicated in several processes, namely, cell cycle, proliferation, migration, survival, metabolism, and angiogenesis, suggesting an epigenetic mechanism related to treatment outcome. These miRNAs may represent attractive prognostic tools to be used in mCRPC management, as well as a step further in the identification of new potential therapeutic targets, to use in combination with ARAT for an improved treatment outcome. Despite the promising results, real-world validation is necessary.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available